top of page

Pediatric DRV/r (pDRV/r) FAQs

  • hivtoolkit
  • Sep 6, 2023
  • 1 min read

This document is meant to answer some of the most common questions that surround pediatric darunavir/ritonavir 120/20mg (pDRV/r) - a new fixed-dose combination of darunavir (DRV)

with ritonavir for children living with HIV (CLHIV) who are at least 3 years old and weigh at least 10kg. Key questions addressed include benefits, potential side effects, price, and considerations for countries when considering adopting and introducing pDRV/r.



Comments


  • LinkedIn
  • Facebook
  • Twitter
  • Instagram
  • YouTube

383 Dorchester Avenue, Suite 400

Boston, MA 02127

The goal of the HIV New Product Introduction Toolkit is to stimulate conversations between government, partners, and communities on new product introduction. Please feel free to share any thoughts, questions, or additional resources for consideration by contacting us via email at HIVToolkit@clintonhealthaccess.org.

 

© 2022  Clinton Health Access Initiative - Global HIV Access Program

bottom of page